GleamWall
中文EN

VICP Vicapsys Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1468639 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-904.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3,053.8%
Debt / equity—
Current ratio0.03x
Interest coverage-62.88x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-819.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-12-31FY20222022-12-31
Income statement
Revenue——
R&D expense$15,267$13,097
SG&A expense$96,431$60,198
Operating income-$1.05M-$984,790
Interest expense$19,969—
Pretax income-$1.18M-$984,790
Net income-$1.18M-$984,790
EPS (basic)-0.03-0.03
EPS (diluted)-0.03-0.03
Weighted avg. shares (diluted)34.55M30.58M
Balance sheet
Cash & equivalents$9,422$14,097
Current assets$39,656$72,021
Total assets$39,656$72,021
Current liabilities$1.97M$1.02M
Short-term debt$18,712—
Total liabilities$1.97M$1.02M
Shareholders' equity-$1.93M-$950,791
Shares outstanding32.07M31.19M
Cash flow statement
Operating cash flow-$417,524-$238,197
Financing cash flow$412,849$34,999
Stock-based compensation$20,697$105,650

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.